Myrelez (Lanreotide Acetate)

Lanreotide acetate is a synthetic somatostatin analog that binds primarily to somatostatin receptor subtypes 2 and 5 on target cells. This binding inhibits adenylate cyclase, lowers intracellular cAMP, and suppresses the release of growth hormone, insulin‑like growth factor‑1, and other peptide hormones, providing hormonal control and antiproliferative effects.

The dosing regimen for Myrelez is individualized by the prescribing clinician based on the patient’s disease severity, response to therapy, and tolerability. Typically, the medication is administered as a long‑acting depot injection given subcutaneously at intervals determined by the treating physician.

Safety of Myrelez in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To order Myrelez, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and assistance with import documentation.

The principal alternative to Myrelez is octreotide, another somatostatin analog. Both agents suppress growth hormone and neuroendocrine hormone secretion, but lanreotide is formulated as a long‑acting depot that can be administered every four weeks, whereas octreotide often requires more frequent dosing or a different depot formulation. Choice between them depends on patient preference, tolerability, and physician assessment.

Myrelez should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours and return the product to refrigeration promptly.

Myrelez is given as a subcutaneous injection using a pre‑filled syringe or vial. The formulation is a long‑acting depot that releases lanreotide slowly over several weeks, allowing dosing intervals typically ranging from four to eight weeks as determined by the prescribing clinician.

Serious risks include gallbladder disease such as gallstones or biliary sludge, acute pancreatitis, severe hyperglycemia that may require medical intervention, and hypersensitivity reactions that can progress to anaphylaxis. Patients should be educated to report abdominal pain, persistent nausea, sudden changes in blood glucose, or signs of an allergic reaction promptly.

Myrelez is contraindicated in individuals with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is advised for patients with severe hepatic impairment, uncontrolled diabetes, or a history of gallbladder disease. The drug should be used under close medical supervision in these populations.